Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC candidate, Rina-S, as registered on ClinicalTrials.gov on October 1, 2024. The trial aims to enroll 530 patients with platinum-resistant advanced ovarian cancer to compare Rina-S head-to-head with chemotherapy, with an anticipated preliminary completion date in February 2027.
Rina-S, originally developed by ProfoundBio (acquired by Genmab in April 2024 for $1.8 billion), was previously known under the development code PRO1184. The ADC features an Fc region with LALA modifications and a payload consisting of an internally developed topoisomerase I inhibitor, LD038.
Immunogen’s Elahere, the first FRα ADC to reach the market globally, has seen rapid sales growth since its launch, reaching $192 million in the first half of the year. AbbVie acquired Immunogen for $10.1 billion in November 2023. Following Immunogen’s lead, Genmab, now with ProfoundBio, is advancing its candidate into Phase III, while Eli Lilly has just initiated a Phase I clinical trial. Additionally, Bristol Myers Squibb has returned rights for Farletuzumab Ecteribulin, originally in-licensed from Eisai.- Flcube.com
